. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: J Thromb Haemost. 2017 May 3;15(6):1078–1085. doi: 10.1111/jth.13689

Table 4.

Longitudinal association between change in plasma PAI-1 and change in LTL among SHFS participants

Sub-populations	N	Multivariate adjusted^*
Sub-populations	N	β^† (SE)	P
Total participants	475	−0.0005 (0.0002)	0.017
Excluding diabetic participants	392	−0.0005 (0.0002)	0.014
Excluding participants under antihypertensive treatment	424	−0.0005 (0.0002)	0.017

LTL: leukocyte telomere length; PAI-1: plasminogen activator inhibitor-1.

Adjusted for age, sex, education level, study site, lifestyle (smoking, drinking), changes in metabolic factors (waist circumference, systolic blood pressure, fasting glucose, insulin, low- and high- density lipoprotein cholesterol, estimated glomerular filtration rate), follow-up years, and baseline plasma PAI-1 and LTL.

^†

Change in LTL (T/S ratio) associated with per unit of change in plasma PAI-1.